Why the study?
Does slow-release oxprenolol reduce the frequency and severity of anginal attacks compared to propranolol in patients with stable exercise-induced angina pectoris?
Does slow-release oxprenolol reduce the frequency and severity of anginal attacks compared to propranolol in patients with stable exercise-induced angina pectoris?
Answers are grounded in this paper and cite their sources.
Supports once-daily oxprenolol as convenient alternative to thrice-daily propranolol in stable angina; confirms equivalent anti-anginal efficacy.
In a double-blind, crossover, randomized study, the therapeutic effectiveness of a single daily dose of slow-release oxprenolol (160 mg/day) was compared with a conventional dosage schedule of propranolol (40 mg three times daily) in eighteen patients with uncomplicated, stable exercise-induced angina pectoris. Compared to control values both drugs produced equipotent reduction in the frequency and severity of anginal attacks accompanied by a significant increase in exercise tolerance, a significant suppression of exercising heart rate and an appreciable reduction in the electrocardiographic evidence of myocardial ischaemia when tested on a treadmill. The possible advantages offered by a single dose treatment with slow-release oxprenolol are discussed.
No takes yet. Share an insight, caveat, or question.
Majid et al. (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: